MX2017016347A - Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. - Google Patents

Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.

Info

Publication number
MX2017016347A
MX2017016347A MX2017016347A MX2017016347A MX2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A
Authority
MX
Mexico
Prior art keywords
sinus node
cardiac myosin
combination therapy
current inhibitor
myosin activator
Prior art date
Application number
MX2017016347A
Other languages
English (en)
Inventor
Andrew Donald Scott Robert
Wasserman Scott
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017016347A publication Critical patent/MX2017016347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen en la presente terapias de combinación para el tratamiento de insuficiencia cardíaca mediante el uso del activador de miosina cardíaca, tal como omecamtiv mecarbil, y un inhibidor de corriente If del nodo sinusal. Se describen adicionalmente en la presente composiciones que comprenden un activador de miosina cardíaca y un inhibidor de corriente If del nodo sinusal.
MX2017016347A 2015-06-26 2016-06-24 Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. MX2017016347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185306P 2015-06-26 2015-06-26
PCT/US2016/039198 WO2016210240A1 (en) 2015-06-26 2016-06-24 Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Publications (1)

Publication Number Publication Date
MX2017016347A true MX2017016347A (es) 2018-08-15

Family

ID=56409184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016347A MX2017016347A (es) 2015-06-26 2016-06-24 Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.

Country Status (7)

Country Link
US (2) US10543215B2 (es)
EP (1) EP3313444B1 (es)
JP (1) JP6858716B2 (es)
AU (1) AU2016282985B2 (es)
CA (1) CA2988796A1 (es)
MX (1) MX2017016347A (es)
WO (1) WO2016210240A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35449A (es) 2013-03-14 2014-09-30 Amgen Inc Compuestos heterocíclicos y sus usos
SI3645518T1 (sl) 2017-06-30 2021-11-30 Amgen Inc. Sinteza omekamtiv mekarbila
BR112019028046A2 (pt) * 2017-06-30 2020-07-07 Amgen Inc. métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos
EP3681882A1 (en) 2017-09-13 2020-07-22 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
MX2023010558A (es) 2021-03-10 2023-11-24 Amgen Inc Sintesis de omecamtiv mecarbil.
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
MXPA06014495A (es) * 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
UY35449A (es) 2013-03-14 2014-09-30 Amgen Inc Compuestos heterocíclicos y sus usos

Also Published As

Publication number Publication date
EP3313444B1 (en) 2020-10-21
EP3313444A1 (en) 2018-05-02
US10543215B2 (en) 2020-01-28
CA2988796A1 (en) 2016-12-29
WO2016210240A1 (en) 2016-12-29
JP6858716B2 (ja) 2021-04-14
AU2016282985A1 (en) 2017-12-14
AU2016282985B2 (en) 2021-07-29
US20180140611A1 (en) 2018-05-24
US20200108076A1 (en) 2020-04-09
JP2018518501A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
CA2956871C (en) Compounds active towards bromodomains
MX2016016337A (es) Polipeptidos apelina.
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
PH12017501279A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
MX2017003516A (es) Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc).
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
EP3576776A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF HEART DEFECTS
EA201991997A1 (ru) Комбинированная терапия
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017001674A (es) Inhibidores de myh7b y usos de los mismos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
PH12020550185A1 (en) Semaglutide in medical therapy
EP3259346A4 (en) P63 inactivation for the treatment of heart failure
MX2015012164A (es) Métodos de tratamiento de enfermedad renal y otros trastornos.